ONE CURE AND RAHAL LETTERMAN LANIGAN RACING EXTEND PARTNERSHIP IN THE BATTLE AGAINST CANCER
One Cure to be Primary Sponsor for Rahal’s entry for two IndyCar Series races in 2020 as well as a full-season associate sponsor
BROWNSBURG, Ind. (September 1, 2019) – Rahal Letterman Lanigan Racing (RLL) announced today that One Cure, an initiative from the Flint Animal Cancer Center at Colorado State University (CSU), has extended their partnership with the team courtesy of an anonymous philanthropist. One Cure will be the primary sponsor of the No. 15 NTT IndyCar Series entry of Graham Rahal at two races in 2020 as well as an associate sponsor for Rahal’s entry for the full 2020 season with the goal of bringing awareness to, and understanding for, One Cure. It will be the third season of the partnership.
“We are grateful to an anonymous philanthropist for making it possible for us to continue to race for One Cure for pets and people with RLL,” said Dr. Christine Hardy, One Cure Program Lead and Director of Operations & Strategy at the Colorado State University Flint Animal Cancer Center. “Graham has been a terrific representative and spokesperson for our program and we are proud to continue this partnership. Additionally, the Graham and Courtney Rahal Foundation and their partners have been valued and generous supporters of the program. Thanks to them we are making progress and helping all cancer patients. Racing for One Cure is racing for hope for all who are fighting this disease.”
One Cure, a project led by CSU’s Flint Animal Cancer Center, utilizes research from innovative cancer treatments for pets involved in clinical trials to benefit people. The center sees more than 1,500 new animal cancer patients every year, with approximately 130 patients enrolling in these carefully monitored clinical trials. These canine and feline patients help to pioneer cancer research, moving treatments out of the laboratory and into clinical practice, ultimately providing hope to the next generation of animal and human cancer patients.
“We have had a tremendous partnership with One Cure for the past two seasons and I am so happy to be able to continue this in 2020,” said Graham Rahal. “Seeing firsthand the impact that the Flint Animal Cancer Center at Colorado State University is making in the fight against cancer in pets and humans has been humbling. Above and beyond being able to help raise awareness, Courtney and I are proud to have been able to raise money for the cause through our foundation golf tournaments. Part of that money has gone toward the Losartan Combination Clinical Trial for children with metastatic bone cancer at Children’s Hospital Colorado and we couldn’t be more proud to support that.”
The 2019 NTT IndyCar Series continues with the Portland Grand Prix, Round 16 of 17 in the NTT IndyCar Series. Graham Rahal has a season-best starting of second place in the One Cure entry at the Honda Grand Prix of Alabama and a season-best finish of third place at Texas Motor Speedway. For more details about the series, please visit www.indycar.com.
About One Cure
Cancer is cancer. One Cure is founded on the principle that cancer affects all creatures and that treatment breakthroughs come through collaboration between scientists and doctors who are working with both people and animals. This approach is known as comparative or translational oncology, and it is the core of the One Cure concept. At the Flint Animal Cancer Center at Colorado State University, their mission is to improve the prevention, diagnosis, and treatment of cancer in pet animals, translating our research and knowledge to also benefit people with cancer. More information about One Cure is available at www.onecure.com.